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Abstract 
Background: We have reported that the phosphatidylinositol-3 kinase (PI3K)/Akt signaling pathway mediated 
Wnt5a-induced osteosarcoma cell migration. However, the signaling pathways regulating Wnt5a/PI3K/Akt-mediated 
cell migration remains poorly defined in osteosarcoma cells.
Methods: We evaluated the activations of RhoA, Rac1 and Cdc42 in osteosarcoma MG-63 and U2OS cells with small 
G-protein activation assay. Boyden chamber assays were used to confirm the migration of cells transfected indi-
cated constructs or siRNA specific against RhoA. A panel of inhibitors of PI3K and Akt treated osteosarcoma cells and 
blocked kinase activity. Western blotting and RhoA activation assay were employed to measure the effect of kinase 
inhibitors and activations of RhoA and Akt.
Results: We found that Wnt5a had a potent stimulatory effect on RhoA activation, but not on Rac1 and Cdc42 activa-
tions. Wnt5a-induced cell migration was largely abolished by siRNA specific against RhoA. DN-RhoA (GFP-RhoA-N19) 
was also capable of retarding Wnt5a-induced cell migration, but the overexpression of CA-RhoA (GFP-RhoA-V14) was 
not able to accelerate cell migration. The Wnt5a-induced activation of RhoA was mostly blocked by pretreatment of 
LY294002 (PI3K inhibitor) and MK-2206 (Akt inhibitor). Furthermore, we found that the Wnt5a-induced activation of 
RhoA was mostly blocked by pretreatment of HS-173 (PI3Kα inhibitor). Lastly, the phosphorylation of Akt (p-Ser473) 
was not altered by transfection with siRNA specific against RhoA or DN-RhoA (GFP-RhoA-N19).
Conclusions: Taken together, we demonstrate that RhoA acts as the downstream of PI3K/Akt signaling (specific 
PI3Kα, Akt1 and Akt2 isoforms) and mediated Wnt5a-induced the migration of osteosarcoma cells.
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Background
The integrity and dynamics of the actin cytoskeleton is 
a key point for cancer cell migrating into adjacent tis-
sues and leading to the cancer metastasis in the distance 
[1, 2]. Actin filaments underlie the plasma membrane 
of mammalian cells, including cancer cells, providing 
strength and shape to its thin lipid bilayer [3]. Regula-
tion of the dynamic behavior and assembly of the actin 
filaments allows cancer cells to build an enormous range 
of structures [4]. There is still largely unknown about the 
molecular mechanisms underlying the dynamics of the 
actin cytoskeleton in cancer metastasis, especially for 
osteosarcoma being characterized by a high malignant 
and metastatic potential.
In vertebrates, the small GTPase Rho regulates the for-
mation and rearrangement of actin filaments, and have 
been implicated in the control of cell motility and inva-
sion [5–7]. Rho GTPases are activated and modify the 
actin cytoskeleton during Xenopus embryogenesis and 
neurite retraction of mouse neuroblastoma cells [8, 9]. 
Rac1, Cdc42 and RhoA have been shown to play vital 
roles in growth factor- or cytokine-induced chemotaxis 
in fibroblasts, macrophages and neutrophils [10–12]. 
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There is also substantial evidence that activation of Rac1, 
Cdc42 and RhoA is necessary for the metastatic behavior 
of cancer cells [12, 13]. However, it is still much uncer-
tainty regarding the signaling pathways trigger Rho pro-
teins to regulate metastatic behavior of cancer cells.
The noncanonical Wnt signaling regulates several 
developmental and oncogenic processes in both insects 
and vertebrates [14]. Wnt5a has been originally classified 
into the noncanonical Wnt signaling. The Wnt5a path-
ways are classified into the following categories for clarity 
and simplicity: (1) Wnt5a/planar cell polarity signaling; 
(2) Wnt5a/Ca2+ signaling; (3) Wnt5a-RAP1 signaling; (4) 
Wnt5a/receptor tyrosine kinase-like orphan receptor 2 
(ROR2) signaling; (5) Wnt5a/protein kinase A signaling; 
(6) Wnt5a/GSK3β signaling; (7) Wnt5a/atypical protein 
kinase C (PKC) signaling; (8) Wnt5a/receptor-like tryo-
sine kinase signaling; and (9) Wnt5a/mammalian target 
of rapamycin signaling [15]. In the previous study, we 
found that the PI3K/Akt signaling pathway mediated 
Wnt5a-induced osteosarcoma cell migration. Here, we 
demonstrates that RhoA acts as the downstream of PI3K/
Akt signaling and mediated Wnt5a-induced the migra-
tion of osteosarcoma cells.
Methods
Cell culture
Human MG-63 and U2OS osteosarcoma cell lines were 
purchased from Cells Resource Center of Shanghai 
Institutes for Biological Sciences, Chinese Academy of 
Sciences (Shanghai, China). These cells were cultured 
in Dulbecco-modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS, Hyclone, 
Logan, UT), at 37  °C in a humidified atmosphere with 
5% CO2. MG-63 cells were plated onto 6-well cell culture 
clusters (Costar) and grown to 80% confluence, and then 
serum-starved for 24  h. These cells were subsequently 
treated with recombinant sfrp2 or Wnt5a (R&D Systems, 
Minneapolis, MN) or PI3K/Akt inhibitors (LY294002, 
HS-173, TGX-221, CZC24832, CAL-101, MK-2206, 
A-674563, CCT128930) (Selleck, Houston, TX) before 
small G-protein activation assays and cell migration 
assays.
Plasmids and small interfering RNA (siRNA)
The constructs GFP-RhoA-N19, GFP-RhoA-V14 and 
vectors were kindly provided by Dr. Zhu (Nanjing 
Medical University, China). RhoA constructs or siRNA 
duplexes specific for RhoA (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) were transiently transfected into 
MG-63 and U2OS cells by using Lipofectamine 2000 
reagent (Invitrogen, Carlsbad, CA) in serum-free OPTI-
MEM according to the manufacturer’s instructions. The 
cells were switched to fresh medium containing 10% FBS 
6 h after the transfection and cultured for 48 h. The cells 
transfected with RhoA constructs or siRNA were used 
for analyzing the expression of these proteins and cell 
migration.
Small G‑protein activation assay
For RhoA, Cdc42 and Rac1 activation assays, MG-63 and 
U2OS cells were seeded into 6-well plates and treated 
with Wnt5a (100 or 200  ng/mL) or indicated PI3K/Akt 
inhibitors [16]. The experiments were then performed 
according to the manufacturer’s protocol (Cytoskeleton 
Inc., Denver, CO, USA). The activation of RhoA, Cdc42 
or Rac1 was normalized to the control group (cells 
treated with vehicle). RhoA, Cdc42 and Rac1 activation 
assays were performed in triplicate.
Cell migration assays
Cell migration was assessed in a modified Boyden cham-
ber (Costar), in which two chambers were separated by 
a polycarbonate membrane (pore diameter, 8.0  μm). 
MG-63 and U2OS cells transfected with RhoA constructs 
or siRNA were grown to subconfluence in 6-well plates 
and then detached. Thereafter, they were centrifuged and 
rendered into single cell suspensions in serum-free cul-
ture medium supplemented with 5 μg/mL BSA. The sus-
pensions containing 5000 cells were added to wells with 
a membrane placed in the bottom. Medium containing 
Wnt5a or vehicle was added to the upper and lower com-
partment of the Boyden chamber. The cells were allowed 
to migrate for 4  h at 37  °C in this assay. Thereafter, the 
medium was discarded, stationary cells were removed 
with a cotton-tipped applicator and the membranes were 
cut out of the chamber and stained with 0.5% crystal vio-
let. The response was evaluated in a light microscope 
(Nikon, Tokyo, Japan) by counting the number of cells 
that had migrated into the membrane.
Western blotting
Subconfluent cells were washed twice with PBS, and 
then lysed with ice-cold RIPA lysis buffer (50  mmol/L 
Tris, 150  mmol/L NaCl, 1% Triton X-100, 1% sodium 
deoxycholate, 0.1% SDS, 1  mmol/L sodium orthova-
nadate, 1  mmol/L sodium fluoride, 1  mmol/L EDTA, 
1 mmol/L PMSF, and 1% cocktail of protease inhibitors) 
(pH7.4). The lysates were then clarified by centrifugating 
at 12,000g for 20 min at 4  °C. The protein extracts were 
separated by SDS-PAGE. The immunoblotting proce-
dure was performed as described [17] and the following 
antibodies were used: rabbit anti-Akt antibody, rabbit 
anti-phospho-Akt (p-Ser473) antibody (Cell Signaling 
Technology, Danvers, MA). Protein bands were detected 
by incubating with horseradish peroxidase-conjugated 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) 
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and visualized with ECL reagent (Thermo Scientific, 
Rockford, IL). The gray values were taken by Tanon imag-
ing analysis system (Tanon, Shanghai, China).
Statistical analysis
All experiments here were repeated at least three times, 
with independent treatments, each of which showed 
essentially the same results. The data were analyzed using 
Student’s t test by SPSS statistical software package. All 
the results were expressed as mean ± SD. For all analyses 
a two-sided p < 0.05 was deemed statistically significant.
Results
RhoA activation was stimulated by Wnt5a treatment 
in osteosarcoma cells
To assess the effect of Wnt5a on Rho activation in human 
osteosarcoma cells, we treated MG-63 and U2OS cells 
with 100 or 200  ng/mL Wnt5a, and measured the Rho 
activation by small G-protein activation assay. We found 
that Wnt5a had a potent stimulatory effect on RhoA acti-
vation, but not on Rac1 and Cdc42 activations (Fig. 1a, b; 
Additional file 1: Figure S1). Sfrp2, an antagonist directly 
binding to Wnt5a, was significantly blocked the stimula-
tory effect of Wnt5a on RhoA activation (Fig. 1c). Thus, 
RhoA activation is regulated by Wnt5a signaling in 
MG-63 osteosarcoma cells.
RhoA mediated the Wnt5a‑induced cell migration
The finding that Wnt5a could induce RhoA activation in 
MG-63 cells prompted us to determine whether RhoA 
activation was required for Wnt5a-mediated cell migra-
tion. Wnt5a-induced cell migration was largely abolished 
by siRNA specific against RhoA (Fig.  2a, d), suggest-
ing that RhoA activation is required for Wnt5a-induced 
migration of MG-63 and U2OS cells. We also used dom-
inant-negative constructs (DN-RhoA) to knock down 
RhoA expression in osteosarcoma cells and checked 
whether Wnt5a-induced cell migration could be inhib-
ited. DN-RhoA (GFP-RhoA-N19) was capable of retard-
ing Wnt5a-induced cell migration (Fig.  2b, e), but the 
overexpression of CA-RhoA (GFP-RhoA-V14) was not 
able to accelerate cell migration (Fig.  2c, e). These find-
ings suggest that RhoA mediates the Wnt5a-induced cell 
migration of osteosarcoma cells.
PI3Kα was required for Wnt5a‑induced RhoA activity 
in osteosarcoma cells
To state the involvement of PI3K in Wnt5a-induced acti-
vation of RhoA, we tested the effect of PI3K inhibitors for 
RhoA activation. Human osteosarcoma cells, pretreated 
with 10 μmol/L LY294002 (PI3K inhibitor) for 1 h, were 
incubated with 100 ng/mL of Wnt5a. The cells were har-
vested 30 min after the start of Wnt5a treatment and the 
cell lysates were subjected to small G-protein activation 
assay. The Wnt5a-induced activation of RhoA was mostly 
blocked by pretreatment of LY294002 (Fig. 3a, c).
Moreover, we want to know which isoforms of PI3K 
regulate the Wnt5a-induced activation of RhoA. MG-63 
and U2OS cells were pretreated with 1  nmol/L HS-173 
(PI3Kα inhibitor), 10 nmol/L TGX-221 (PI3Kβ inhibitor), 
10  nmol/L CZC24832 (PI3Kγ inhibitor) and 10  nmol/L 
CAL-101 (PI3Kδ inhibitor), respectively, then were 
incubated with 100  ng/mL Wnt5a. The Wnt5a-induced 
activation of RhoA was mostly blocked by pretreatment 
Fig. 1 Wnt5a triggers RhoA activation of osteosarcoma cells. (a and b) Human osteosarcoma cells MG-63 (a) and U20S (b), serum-deprived for 
24 h, were untreated or treated with 100 ng/mL of Wnt5a and harvested at 30 min after the start of treatment for small G-protein activation assays. 
Data were presented as mean ± SD of 3 determinations. The relative Rho activity was normalized to the average value of Wnt5a-untreated group. 
c Serum-deprived MG-63 cells were pre-treated with 1 µg/mL sfrp2 (an antagonist that directly binds to Wnt5a) for 1 h, then were incubated with 
100 ng/mL Wnt5a and harvested at 30 min after the start of Wnt5a treatment. Data were presented as mean ± SD of 3 determinations. The relative 
RhoA activity was normalized to the average value of sfrp2-untreated group
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of HS-173 and TGX-221 in MG-63 cells, respectively 
(Fig.  3b). However, Wnt5a-induced activation of RhoA 
was only blocked by pretreatment of HS-173 in U2OS 
cells (Fig.  3d). These data indicate that PI3Kα mediates 
Wnt5a-induced activation of RhoA in osteosarcoma cells.
Akt1 and Akt2 were required for Wnt5a‑induced RhoA 
activity in osteosarcoma cells
To demonstrate the involvement of Akt in Wnt5a-
induced activation of RhoA, we tested the effect of Akt 
inhibitors for RhoA activation. Osteosarcoma cells, 
Fig. 2 RhoA activation is required for Wnt5a-induced cell migration. Cell migration rate was determined by using Boyden chamber assays in MG-63 
and U20S cells incubated in the absence (0 ng/mL) or presence of 100 ng/mL Wnt5a for 4 h. a, d MG-63 (a) and U20S cells (d) were transfected with 
RhoA-siRNA or scrambled siRNA (NC), then subjected to Boyden chamber assays. b, e MG-63 (b) and U20S cells (e) were transfected with GFP-
RhoA-N19 (DN-RhoA) or vector, then subjected to Boyden chamber assays. c, e MG-63 (c) and U20S cells (e) were transfected with GFP-RhoA-V14 
(CA-RhoA) or vector, then subjected to Boyden chamber assays. All data were presented as mean ± SD of 3 determinations
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pretreated with 10 nmol/L MK-2206 (Akt inhibitor) for 
1 h, were incubated with 100 ng/mL of Wnt5a. The cells 
were harvested 30  min after the start of Wnt5a treat-
ment and the cell lysates were subjected to small G-pro-
tein activation assay. The Wnt5a-induced activation of 
RhoA was mostly blocked by pretreatment of MK-2206 
(Fig. 4a, c).
Moreover, we want to know which isoforms of Akt reg-
ulate the Wnt5a-induced activation of RhoA. MG-63 and 
U2OS cells were pretreated with 10  nmol/L A-674563 
(Akt1 inhibitor) and 10 nmol/L CCT128930 (Akt2 inhibi-
tor), respectively, then were incubated with 100  ng/
mL Wnt5a. The Wnt5a-induced activation of RhoA 
was mostly blocked by pretreatment of A-674563 and 
CCT128930, respectively (Fig. 4b, d). These data indicate 
that Akt1 and Akt2 mediate Wnt5a-induced activation of 
RhoA in osteosarcoma cells.
RhoA acted as the downstream of Wnt5a/PI3K/Akt 
signaling
We next examined whether RhoA was downstream 
of PI3K/Akt in human osteosarcoma cells. MG-63 
cells, transfected with RhoA-siRNA, were treated 
with 100  ng/mL of Wnt5a. The cells were harvested 
at 30 min after the start of Wnt5a treatment, followed 
by SDS-PAGE and Western blotting analyses. Akt 
showed unchanged signs of phosphorylation at Ser473, 
which represents the Akt activation state, after Wnt5a 
treatment (Fig.  5a). The same assays were performed 
to detect the phosphorylated of Akt after DN-RhoA 
(GFP-RhoA-N19) transfection, the phosphorylation of 
Akt was also not altered after stimulation with Wnt5a 
(Fig. 5b, c).
In conclusion, RhoA acts as the downstream of PI3K/
Akt signaling (specific PI3KαAkt1 and Akt2 isoforms) 
Fig. 3 PI3 Kα isoform is required for Wnt5a-induced RhoA activity. a, c Human osteosarcoma cells MG-63 (a) and U20S (c), serum-deprived for 24 h, 
were pre-treated with 10 µmol/L LY294002 (PI3K inhibitor) for 1 h, were incubated with 100 ng/mL Wnt5a and harvested at 30 min after the start of 
Wnt5a treatment. The relative RhoA activity was normalized to the average value of LY294002/Wnt5a-untreated group. b, d Serum-deprived MG-63 
(b) and U20S cells (d) were pre-treated with 1 nmol/L HS-173 (PI3Kα inhibitor), 10 nmol/L TGX-221 (PI3Kβ inhibitor), 10 nmol/L CZC24832 (PI3Kγ 
inhibitor) and 10 nmol/L CAL-101 (PI3Kδ inhibitor) for 1 h, then were incubated with 100 ng/mL Wnt5a and harvested at 30 min after the start of 
Wnt5a treatment. Data were presented as mean ± SD of 3 determinations. The relative RhoA activity was normalized to the average value of each 
inhibitor-untreated group
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and mediated Wnt5a-induced the migration of osteosar-
coma cells (Fig. 5d).
Discussion
Wnt5a, a prototypic ligand that activates a β-catenin 
independent pathway in Wnt signaling, has been demon-
strated to exert differential effects on cancer development 
[18, 19]. Wnt5a promotes breast cancer cell migration via 
Dishevelled 2 (Dvl2)/Dishevelled-associated activator of 
morphogenesis 1 (Daam1)/RhoA signaling pathway [20]. 
Wnt5a-Ror2 signaling enhances expression of CXCL16 
in mesenchymal stem cells (MSCs) and enhanced secre-
tion of CXCL16 from MSCs, leading to the promo-
tion of its proliferation [21]. In the previous study, we 
have found that Wnt5a induces the migration of MG-63 
osteosarcoma cells by triggering PI3K/Akt signaling, 
suggesting that Wnt5a acts as a migratory stimulator in 
osteosarcoma cells [16]. Thus, 100  ng/mL Wnt5a was 
used in study to identify the mechanism whereby changes 
in the migration of osteosarcoma cells were induced.
PI3Ks are a family of  enzymes  involved in cellular 
functions such as cell growth, proliferation, differen-
tiation, motility, survival and intracellular trafficking, at 
least including four isoforms (PI3Kα, PI3Kβ, PI3Kγ and 
PI3Kδ) [22]. Akt, also known as protein kinase B (PKB), is 
the direct target of PI3K, including three isoforms (Akt1, 
Akt2 and Akt3) [23]. It is still largely unknown which 
isoforms of PI3Ks and Akts regulate the Wnt5a-induced 
migration of osteosarcoma cells. Because Akt3 appears to 
be predominantly expressed in the brain [24], we used the 
specific inhibitors to block PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, 
Akt1 and Akt2 activity and studies the effects of each iso-
form of PI3Ks and Akts in osteosarcoma cell migration in 
this study. Here, PI3Kα, PI3Kβ, Akt1 and Akt2 isoforms 
regulate Wnt5a-induced osteosarcoma cell migration.
RhoA promotes focal adhesion and regulates cell con-
tractility, leading to the cell migration [25]. Wnt3a trig-
gers RhoA activity to regulate neurite retraction of mouse 
neuroblastoma cells [8]. RhoA is involved in Wnt5a 
signaling and promotes the migration of MDA-MB-231 
Fig. 4 Akt1 and Akt2 isoforms are required for Wnt5a-induced RhoA activity. a, c Human osteosarcoma cells MG-63 (a) and U20S (c), serum-
deprived for 24 h, were pre-treated with 10 nmol/L MK-2206 (Akt inhibitor) for 1 h, were incubated with 100 ng/mL Wnt5a and harvested at 30 min 
after the start of Wnt5a treatment. The relative RhoA activity was normalized to the average value of LY294002/Wnt5a-untreated group. b, d Serum-
deprived MG-63 (b) and U20S cells (d) were pre-treated with 10 nmol/L A-674563 (Akt1 inhibitor) and 10 nmol/L CCT128930 (Akt2 inhibitor) for 1 h, 
then were incubated with 100 ng/mL Wnt5a and harvested at 30 min after the start of Wnt5a treatment. Data were presented as mean ± SD of 3 
determinations. The relative RhoA activity was normalized to the average value of each inhibitor-untreated group
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breast cancer cells [20]. In gastric cancer cells, down-
regulation of PI3K/Akt/GSK3β signaling in SGC-7901 
cells suppressed Wnt5a-induced activation of RhoA [17]. 
In this study, we demonstrated that RhoA activation acts 
as the downstream of Wnt5a/PI3K/Akt signaling, and is 
specifically regulated by PI3Kα, Akt1 and Akt2 isoforms 
in osteosarcoma cells.
Conclusions
We present the evidence here that RhoA mediates 
Wnt5a-induced osteosarcoma cell migration via PI3Kα, 
Akt1 and Akt2 isoforms. These findings elucidate a 
molecular pathway linking RhoA signaling to Wnt5a/
PI3K/Akt in cell motility. This result will contribute to 
further understanding of biological roles of Wnt5a/PI3K/
Akt/RhoA in cell migration of osteosarcoma and other 
cancers.
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